Which has the lower trailing P/E, KNSA or LGND?

LGND has the lower trailing P/E: KNSA trades at 77.77 and LGND at 32.09. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, KNSA or LGND?

Over the past five years, KNSA grew revenue faster — KNSA at a 155.66% CAGR versus LGND at 2.92%.

Is KNSA or LGND more profitable?

LGND runs the higher net margin — KNSA at 9.59% versus LGND at 67.88%.

How have KNSA and LGND total returns compared?

Over the past 5 years, KNSA delivered 47.48% and LGND delivered 30.72% annualized total return. Past performance doesn't predict future results.

Kiniksa Pharmaceuticals International, plc (KNSA) vs Ligand Pharmaceuticals Incorporated (LGND)

A side-by-side comparison of Kiniksa Pharmaceuticals International, plc and Ligand Pharmaceuticals Incorporated across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

KNSA

Kiniksa Pharmaceuticals International, plc

$5.81B

$76.21HealthcareDelayed quote: Oct 6, 2026, 11:34 AM EDT

LGND

Ligand Pharmaceuticals Incorporated

$6.01B

$300.03HealthcareDelayed quote: Oct 6, 2026, 11:35 AM EDT

Total return — KNSA vs LGND

growth of $100 · dividends reinvested · last 8y

KNSA +291.9% (+18.6%/yr)LGND +152.2% (+12.3%/yr)KNSA compounded faster over this window

KNSA LGND

KNSA vs LGND: by the numbers

•LGND is the larger company ($6.01B vs $5.81B market cap).
•LGND trades at the lower trailing earnings multiple (32.09 vs 77.77 P/E), one valuation lens rather than an overall verdict.
•LGND converts more revenue to profit (67.88% vs 9.59% net margin).
•KNSA grew revenue faster over the past five years (155.66% vs 2.92% CAGR).

Metrics side by side

Valuation

Metric	KNSA	LGND
P/E ratio	77.77	32.09
Forward P/E	54.72	32.24
P/S ratio	6.91	20.70
P/B ratio	8.88	6.21
EV / EBITDA	55.28	45.48
FCF yield	3.15%	2.18%

Profitability

Metric	KNSA	LGND
Gross margin	54.49%	98.58%
Operating margin	11.92%	17.61%
Net margin	9.59%	67.88%
ROE	12.33%	20.38%
ROIC	9.76%	3.91%

Growth (annualized)

Metric	KNSA	LGND
Revenue CAGR (5Y)	155.66%	2.92%
FCF CAGR (5Y)	N/A	-0.49%
Total return CAGR (5Y)	47.48%	30.72%

Frequently asked

Which has the lower trailing P/E, KNSA or LGND?: LGND has the lower trailing P/E: KNSA trades at 77.77 and LGND at 32.09. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, KNSA or LGND?: Over the past five years, KNSA grew revenue faster — KNSA at a 155.66% CAGR versus LGND at 2.92%.
Is KNSA or LGND more profitable?: LGND runs the higher net margin — KNSA at 9.59% versus LGND at 67.88%.
How have KNSA and LGND total returns compared?: Over the past 5 years, KNSA delivered 47.48% and LGND delivered 30.72% annualized total return. Past performance doesn't predict future results.

Go deeper

Full KNSA analysis Full LGND analysis Interactive comparison tool

Dig into the metrics

Kiniksa Pharmaceuticals International P/E ratio Ligand Pharmaceuticals P/E ratio Kiniksa Pharmaceuticals International ROE Ligand Pharmaceuticals ROE Kiniksa Pharmaceuticals International operating margin Ligand Pharmaceuticals operating margin Kiniksa Pharmaceuticals International revenue growth Ligand Pharmaceuticals revenue growth Kiniksa Pharmaceuticals International free cash flow Ligand Pharmaceuticals free cash flow

Kiniksa Pharmaceuticals International & Ligand Pharmaceuticals appear in these rankings

Fastest Revenue Growth Stocks Highest 10-Year Total Return Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.